S100β protein: The preoperative new clinical indicator of brain damage in patients with fulminant hepatic failure

S. Shiotani, M. Shimada, Y. Soejima, T. Yoshizumi, S. Uemoto, T. Kiuchi, K. Tanaka, Y. Maehara

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The aim of this study was to clarify the role of serum S100β on the accurate assessment of reversibility of brain damage after fulminant hepatic failure (FHF). Among the 13 patients with FHF enrolled in this study, 12 underwent living donor liver transplantation; one patient could not the procedure because of volvulus of the sigmoid colon. Serum S100β was serially measured using a chemiluminescent immunoassay. Preoperative serum S100β in patients with diffuse brain edema was significantly higher than that in patients with localized brain edema (P < 0.05). Patients with preoperative brain death showed serum S100β levels over 7.0 μg/L. Serum S100β levels correlated with the degree of brain edema of FHF. It has the potential to be a new clinical, noninvasive indicator of brain damage due to FHF.

Original languageEnglish
Pages (from-to)2713-2716
Number of pages4
JournalTransplantation Proceedings
Volume36
Issue number9
DOIs
Publication statusPublished - Nov 2004

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'S100β protein: The preoperative new clinical indicator of brain damage in patients with fulminant hepatic failure'. Together they form a unique fingerprint.

Cite this